Cantor Fitzgerald Maintains Overweight on Mirum Pharmaceuticals, Raises Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer maintains an Overweight rating on Mirum Pharmaceuticals (NASDAQ:MIRM) and raises the price target from $35 to $40.

March 04, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald analyst Josh Schimmer maintains an Overweight rating on Mirum Pharmaceuticals and raises the price target from $35 to $40.
The increase in price target by a reputable analyst firm like Cantor Fitzgerald typically signals a strong bullish sentiment towards the company's stock. This adjustment reflects positive expectations for Mirum Pharmaceuticals' performance, likely based on the company's recent developments, financial health, or market position. Such endorsements can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100